Back to today’s briefing

Story perspectives

FDA's New Drug Review Program Sparks Controversy and Concern

12/20/2025

48 11

Summary

Story summary

The Food and Drug Administration has launched a program to expedite drug reviews.
Historically, the FDA kept evaluations under career scientists to prevent political interference.
High-level officials are now involved in the Commissioner’s National Priority Review vouchers, awarding at least one despite staff objections.
Career scientists say political pressure undermines established processes for ensuring drug safety and efficacy.

1 of 1

Story summary

The Food and Drug Administration has launched a program to expedite drug reviews.
Historically, the FDA kept evaluations under career scientists to prevent political interference.
High-level officials are now involved in the Commissioner’s National Priority Review vouchers, awarding at least one despite staff objections.
Career scientists say political pressure undermines established processes for ensuring drug safety and efficacy.